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Abstract 
Recent evidence implicates adaptive immunity as a key player in the mechanisms supporting 
hepatic inflammation during the progression of nonalcoholic fatty liver disease (NAFLD). In these 
settings, patients with NAFLD often show an increase in the circulating levels of antibodies against 
oxidative stress-derived epitopes (OSE).  Nonetheless, the actual role of humoral immunity in 
NAFLD is still unclear.  This study investigates the contribution of B-lymphocytes to NAFLD 
evolution. 
B-lymphocyte immunostaining of liver biopsies from NAFLD patients showed that B-cells were 
evident within cell aggregates rich in T-lymphocytes. In these subjects, B/T-lymphocyte infiltration 
positively correlated with both circulating IgG targeting oxidative stress-derived epitopes (OSE) 
and interferon-γ (IFN-γ) levels. Furthermore, high prevalence of lymphocyte aggregates identified 
patients with more severe lobular inflammation and fibrosis. In mouse models of NAFLD, the onset 
of steatohepatitis was characterized by hepatic B2-lymphocytes maturation to plasma cells and by 
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an elevation in circulating anti-OSE IgG titers. B-cell responses preceded T-cell activation and were 
accompanied by the up-regulation in the hepatic expression of B-cell Activating Factor (BAFF). 
Selective B2-cell depletion in mice over-expressing a soluble form of the BAFF/APRIL receptor 
Transmembrane Activator and Cyclophilin Ligand Interactor (TACI-Ig) prevented plasma cell 
maturation and Th-1 activation of liver CD4+ T-lymphocytes. Furthermore, TACI-Ig mice showed 
milder steatohepatitis and a decreased progression to fibrosis. Similarly, mice treatment with the 
BAFF-neutralizing monoclonal antibody Sandy-2 prevented hepatic B2-cell responses and 
ameliorated steatohepatitis.  
From these data we conclude that B2-lymphocyte activation is an early event in NAFLD evolution 
and contributes to the disease progression through the interaction with T-cells. Furthermore, 
combined clinical and experimental data suggest that elevated circulating anti-OSE IgG can identify 
a subset of NAFLD patients in whom adaptive immunity has a relevant role in the disease 
evolution toward fibrosis.    
 
Abbreviations: BAFF, B-cell Activating Factor; CDAA, choline-deficient and amino acid defined ; 
IFN-γ, interferon-γ  ; NAFLD, nonalcoholic fatty liver disease ; NASH, nonalcoholic steatohepatitis; 
MHCII, class II Major Histocompatibility Complex ; MCD, methionine-choline deficient ; MDA,  
malonyl-dialdehyde ; OSE, oxidative stress-derived epitopes ; α-SMA, α-smooth muscle actin ; 
TACI, Transmembrane Activator and Cyclophilin Ligand Interactor; TGF-β1, Transforming Growth 
Factor-β1; TNF-α, Tumor Necrosis Factor-α 
 
Keywords: Nonalcoholic steatohepatitis, immune responses, lipid peroxidation, liver 
inflammation, liver fibrosis.  
 
Introduction 
In the last decade, nonalcoholic fatty liver disease (NAFLD) has emerged as a growing cause of liver 
fibrosis/cirrhosis, while end-stage nonalcoholic steatohepatitis (NASH) is already the second most 
common indication for liver transplantation in the United States [1]. Moreover, NAFLD/NASH is 
increasingly recognized as an important cause of hepatocellular carcinoma (HCC) [2].    Beside the 
effects on the liver, epidemiological data indicate a strong association between NAFLD and the 
prevalence of extra-hepatic complications, such as type 2 diabetes mellitus, cardiovascular 
diseases, chronic kidney disease and osteoporosis [3]. In all these settings, hepatic inflammation 
that characterizes NAFLD evolution to nonalcoholic steatohepatitis (NASH) is considered the 
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driving force for the progression to cirrhosis as well as an independent risk factor for extrahepatic 
complications [3]. However, the mechanisms responsible for steatohepatitis are still incompletely 
understood.   
Several factors have been proposed to sustain hepatic inflammation in NASH pathogenesis. 
Among these, the best characterized are persistent parenchymal injury due to oxidative stress and 
lipotoxicity, as well as inflammasome activation and the direct stimulation of Kupffer cells by 
either excess of circulating free fatty acids and cholesterol or by gut-derived bacterial products [4-
7]. As a result, circulating monocytes are recruited within the liver and, by differentiating into M1 
polarized macrophages, further contribute to the release of pro-inflammatory mediators and to 
oxidative stress-induced damage [8]. Although these mechanisms implicate an extensive 
involvement of innate immunity, they do not explain the large inter-individual variability in the 
development of hepatic inflammation.  
An emerging body of evidence indicates that, besides the role of innate immune responses, NASH 
is also characterized by the involvement of adaptive immunity. Indeed, lobular and portal 
lymphocyte infiltration is a histological feature of human NASH [9], while experimental NASH 
models show that CD4+ and CD8+ T-lymphocytes, B-lymphocytes and natural killer T-cells (NKT) are 
recruited within the liver in parallel with the worsening of steatohepatitis [10,11]. T-cell subsets in 
NASH livers express activation markers (CD44, CD69) and show an enhanced production of 
interferon-γ (IFN-γ), interleukin (IL)-17A, IL-17F and tumor necrosis factor superfamily member 14 
(TNFSF14; LIGHT), indicating that lymphocytes infiltrating the liver are functionally activated [9-
11]. These findings are supported by clinical observations showing that human NASH is 
characterized by an increase in circulating IFN-γ-producing CD4+ T-cells as well as enhanced IFN-γ 
production within the liver [12,13] in relation to CD8+ T- and NKT-cell infiltration [9,14]. 
Conversely, the severity of experimental NASH is greatly lowered in Rag1-/- mice, which are unable 
to mount adaptive immune responses [9]. Accordingly, the lack of CD8+ T- and NKT-cells as well as 
LIGHT, IFN-γ and IL-17 deficiencies ameliorate steatohepatitis and prevent its evolution to HCC [9, 
11,15].  In these settings, we have shown that epitopes derived from oxidative stress (OSE), 
namely malonyldialdehyde (MDA) and 4-hydroxynonenal (4-HNE) protein adducts, are involved in 
the activation of adaptive immunity in NASH [10]. In fact, mice treatment with antioxidants lowers 
immune responses [16], whereas the immunization with MDA-adducts before NASH induction 
further stimulates lobular inflammation by promoting Th-1 activation of liver CD4+ helper T-cells 
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[10]. Besides T-cell-mediated immunity, experimental NASH is also characterized by humoral 
immune responses involving the production of IgG against OSE [10,16].  Elevated titers of the 
same antibodies are detectable NAFLD/NASH patients in whom are associated with increased 
hepatic inflammation [17,18] and are an independent predictor of advanced fibrosis [17].  
These observations show many analogies with data implicating B-lymphocytes infiltrating the 
adipose tissue as important players in causing insulin resistance and systemic inflammation in 
obesity [19,20].  In more detail, B-cells isolated from visceral fat of obese mice show an increased 
production of pro-inflammatory cytokines, while their accumulation in the adipose tissue 
associates with T-cell and macrophage activation [21-23]. Moreover, fat inflammation and insulin 
resistance are lowered in mice lacking B-cells or following B-cell depletion using anti-CD20 
antibodies [23].  From this background we investigated the role of B-lymphocytes in the 
pathogenesis of NASH.   
 
Materials & Methods 
Human specimen collection and analysis 
Liver biopsies and sera from 41 consecutive patients with NAFLD/NASH, referring to the Liver Unit 
of the University Hospital of Novara from 2011 to 2016, were analyzed. All samples were collected 
at the time of first diagnosis. Patients were characterized by anthropometric, clinical and 
biochemical data and liver biopsies were evaluated for the severity of steatohepatitis and fibrosis 
according to Kleiner et al. [24]. All subjects gave informed consent to the analysis and the study 
was planned according to the guidelines of the local ethical committee. The clinical and 
biochemical features of patients are reported in Supplementary Table 1.  Serum samples from 
NAFLD/NASH patients together with those of 32 age/gender matched healthy subjects recruited 
among blood donors were investigated for the presence of IgG reactivity toward OSE by an in 
house enzyme-linked immunosorbent assay (ELISA) using as antigen malonyl-dialdehyde adducts 
with human serum albumin (MDA-HSA) [17]. Circulating interferon-γ (IFN-γ) was also measured in 
34 sera of these patients by commercial kits supplied by Peprotech (Milano, Italy).  
Animals and experimental protocol 
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Transgenic TACI-Ig mice on C57BL/6 background were a kind gift of Dr. A. Villunger (Division of 
Developmental Immunology, Biocenter, Medical University Innsbruck, Innsbruck, Austria). These 
mice overexpress a soluble form of the BAFF/APRIL receptor Transmembrane Activator and 
Cyclophilin Ligand Interactor (TACI; TNFRSF13B) fused with the Fc portion of human IgG1 and are 
characterized by an impaired B-cell maturation in the periphery, leading to a severe depletion of 
marginal zone and follicular B2-lymphocytes, but not of peritoneal B1-cells [25].  Eight-week-old 
male wild type and TACI-Ig mice were fed ad libitum with either methionine/choline deficient 
(MCD) diet for 1 or 4 weeks or with a choline deficient and amino acid defined (CDAA) diet for 12 
or 24 weeks (Laboratorio Dottori Piccioni, Gessate, Italy). Control animals received the same diets 
supplemented by either choline/methionine or choline. In some experiments, mice were injected 
intra-peritoneally with the BAFF neutralizing monoclonal mouse IgG1 Sandy-2 [26] (2 µg/g body 
weight; Adipogen, Liestal, Switzerland) at the start and after two weeks of MCD diet. Control 
animals received isotype-matched IgG. The animals were housed at 22°C with alternating 12 hours 
light/dark cycles. The mice were not fasted before sample collections. In all the experiments 
euthanasia was performed under isofluorane anesthesia between 9 a.m. and 12 a.m. The 
experimental procedures complied with the EU guidelines for animal experimentation and were 
approved by the Italian Ministry of Health. 
Biochemical analysis 
Plasma alanine aminotransferase (ALT) and liver triglycerides were determined by spectrometric 
kits supplied by Gesan Production S.r.l. (Campobello di Mazara, Italy) and Sigma Diagnostics 
(Milan, Italy), respectively. Circulating TNF-α was evaluated by commercial ELISA kits supplied by 
Peprotech (Milano, Italy).  Anti-OSE IgG reactivity in mice sera was evaluated as previously 
reported [10]. 
Histology and immunohistochemistry 
Serial sections from paraffin-embedded human liver biopsies were immune-stained with anti-
CD20 and anti-CD3 antibodies (Roche/Ventana, Tucson, AZ, USA) using Bond Polymer Refined 
Detection kit on the Bond Max auto-stainer (Leika Biosystems, Wetzlar, Germany). The presence 
of B-/T-cell aggregates was evaluated semi-quantitatively according to the size and number. 
Hematoxylin/eosin stained mouse liver sections were scored blindly for steatosis, lobular 
inflammation and fibrosis [10]. Collagen deposition was detected by Picro-Sirius Red staining. Liver 
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activated hepatic stellate cells were evidenced in formalin-fixed sections using an α-smooth 
muscle actin (α-SMA) polyclonal antibody (Labvision, Bio-Optica, Milan, Italy) in combination with 
a horseradish peroxidase polymer kit (Biocare Medical, Concord, CA, USA). The extension of Sirius 
Red and α-SMA-positive areas was quantified by histo-morphometric analysis using the ImageJ 
software (https://imagej.nih.gov/ij/). 
Intrahepatic mononucleated cell isolation and flow cytometry analysis 
Liver mononucleated cells were isolated from the livers of naive and MCD-fed mice and purified 
on a density gradient (Lympholyte®-M, Cedarlane Laboratoires Ltd. Burlington, Canada) as 
described in [27]. Cells were washed with Hank’s medium and incubated 30 min with de-
complemented mouse serum to block nonspecific immunoglobulin binding. The cells were then 
stained with fluorochrome-conjugated antibodies for CD45, CD3, CD4, CD8, B220, IgM, CD69, 
CD23, CD43, MHCII CD11c, CD80 (eBiosciences, San Diego CA, USA), CD138 (BD Biosciences, 
Franklin Lakes, NJ, USA) and analyzed with a FACScalibur (Becton Dikinson, Franklin Lakes, NJ, USA) 
or AttuneTM NxT (Thermo Fischer Scientific, Waltham, MS, USA) flow cytometers. Intracellular 
staining for TNF-α, IFN-γ and IL-10 was performed using specific fluorochrome-conjugated 
antibodies (eBiosciences, San Diego CA, USA) after cell permeabilization with saponin 
(Permeabilization Kit, eBiosciences, San Diego CA, USA). Single cells were pre-gated on CD45+. 
mRNA extraction and Real time PCR 
Liver RNA was retro-transcribed with the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems Italia, Monza, Italy) in a Techne TC-312 thermocycler (TecneInc, Burlington NJ, USA). 
Real Time PCR was performed in a CFX96™ Real-time PCR System (Bio-Rad, Hercules, California, 
USA) using TaqMan Gene Expression Master Mix and TaqMan Gene Expression probes for mouse 
TNF-α, IL-12p40, CCL2, CXCL10, IFN-γ, CD154, T-bet, BAFF, APRIL, α1-procollagen, TGF-β1, α-SMA 
and beta-actin (Applied Biosystems Italia, Monza, Italy). All samples were run in duplicate and the 
relative gene expression was calculated as 2-ΔCt over that of β-actin gene. The values were 
expressed as fold increase over control samples.  
Data analysis and statistical calculations 
Statistical analyses were performed by SPSS statistical software (SPSS Inc. Chicago IL, USA) using 
one-way ANOVA test with Tukey’s correction for multiple comparisons or Kruskal-Wallis test for 
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non-parametric values. Significance was taken at the 5% level. Normality distribution was 
preliminarily assessed by the Kolmogorov-Smirnov algorithm. 
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Results 
B- and T-lymphocyte responses in human NASH. 
We previously reported that NAFLD/NASH patients have humoral immunity against OSE [18,19]. 
These findings were confirmed in the present study by measuring circulating IgG targeting MDA-
derived adducts in a new cohort of 41 patients (17 male/24 female) with histological diagnosis of 
NAFLD/NASH. Among these patients, 10 (24%) had steatosis only, 7 (17%) steatosis with mild 
lobular inflammation, while the remaining 24 (59%) had NASH with variable degrees of fibrosis. As 
shown in Figure 1A, 18 (43%) of NAFLD/NASH patients had titers of anti-OSE IgG above the control 
threshold. Furthermore, in agreement with previous observations [17], the prevalence of 
advanced fibrosis or cirrhosis (staging ≥2) was higher among the subjects with elevated anti-OSE 
IgG as compared to those with anti-OSE reactivity within the control range (OR=3.25; 95% CI 1.03-
15; p=0.05). As compared to healthy controls, NAFLD/NASH patients had also elevated circulating 
IFN-γ levels (Fig. 1B). Serum IFN-γ was higher among NAFLD/NASH patients showing high anti-OSE 
IgG reactivity (Fig. 1C) and positively correlated with the severity of fibrosis (Spearman r=0.59; 95% 
CI 0.07-0.86; p=0.03). Immunostaining of serial sections from liver biopsies of the same patients 
using, respectively, the B-cell marker CD20 and the T-cell marker CD3 showed that in 26 (63%) 
liver specimens CD20+ B-cells were evident within mononucleated cell aggregates rich of CD3+ T-
lymphocytes (Fig 1D). The prevalence of B/T-lymphocyte infiltration was independent from age, 
BMI, HOMA-IR, transaminase release and the degree of steatosis. However, NAFLD/NASH patients 
with marked/high B-/T-cell infiltration had elevated anti-OSE IgG titers (Fig. 1E) as well as higher 
scores of lobular inflammation and fibrosis than the subjects with low/mild infiltration (Fig. 1F-G). 
The number and size of lymphocyte aggregates also positively correlated with circulating IFN-γ 
levels (Spearman r=0.45; 95% CI 0.005-0.048; p=0.02), lobular inflammation score (Spearman 
r=0.45; 95% CI 0.17-0.67; p=0.003 and r=0.39; 95% CI 0.10-0.62; p=0.01) and fibrosis staging 
(Spearman r=0.44; 95% CI 0.15-0.66; p=0.004 and r=0.41; 95% CI 0.11-0.63; p=0.008), suggesting a 
functional interplay between humoral and cellular immunity in the processes leading to NASH 
progression. 
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Changes in liver B-lymphocytes during the evolution of experimental NASH 
Based on these observations, we sought to dissect the actual role of liver B-cells in the processes 
involved in NASH evolution. As obesity has been shown to promote B-cell activation that, on its 
turn, influences insulin resistance and systemic inflammation [19,20], for these experiments we 
relied on obesity-independent models of steatohepatitis based on the administration of a 
methionine/choline deficient (MCD) or a choline-deficient and amino acid defined (CDAA) diets 
[28]. These models were also chosen because, according to previous studies [9,10], they 
reproduce liver lymphocyte responses associated to human NAFLD/NASH.  In mice receiving the 
MCD diet, flow cytometry analysis of liver myeloid cells revealed that the number of IgM+/B220+ 
hepatic B-lymphocytes significantly declined after one week of treatment (Fig. 2A) in parallel with 
the onset of steatohepatitis (Supplementary Fig. 1). Such an effect specifically involved the 
fraction of B220+/CD43-/CD23+ B2-lymphocytes, while the pool of B220+/CD43+/CD23- B1-cells was 
unmodified (Supplementary Fig. 2A-B). Liver B-cell lowering was accompanied by a concomitant 
up-regulation in the expression of the early lymphocyte activation marker CD69 among B220+ cells 
(Supplementary Fig. 2C) and by the expansion of B220+/CD138+ plasma blasts and B220-/CD138+ 
plasma cells (Fig. 2B). In the same animals, we also detected an increase in the titers of circulating 
anti-OSE IgG (Fig. 2C), without changes in IgM reactivity against the same antigens (Fig. 2D), 
indicating B2-cell maturation toward IgG-producing plasma cells. Similar changes in liver B-cell and 
plasma cell compartments were also observed in mice with steatohepatitis induced by 12 weeks 
feeding with the CDAA diet (Supplementary Fig. 3).    B-cell responses in NASH were associated to 
the up-regulation in the liver expression of B-cell Activating Factor (BAFF; TNFSF13b), one of the 
cytokines regulating B-cell survival and maturation [28] (Supplementary Fig. 2D). No changes were 
instead observed for the other B-cell regulating cytokine A Proliferation Inducing Ligand (APRIL; 
TNFSF13) (Supplementary Fig. 2E). 
 
B2-lymphocyte deficiency interferes with the onset of immune response in NASH 
It is well known that B-lymphocytes can act as antigen presenting cells for CD4+ T-cells through the 
expression of class II Major Histocompatibility Complex (MHCII) and costimulatory molecules [30]. 
Time-course experiments revealed that an early up-regulation of MHCII among CD138+ plasma 
blasts and plasma cells (Supplementary Fig. 2F-G). Furthermore, B-cell activation preceded the 
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liver recruitment/activation of both CD4+ and CD8+ T-lymphocytes as well as the up-regulation of 
liver mRNAs for the Th-1 activation markers IFN-γ, T-bet and CD40 ligand (CD154) (Supplementary 
Fig. 4A & B). To investigate the possible role of B2-lymphocytes in modulating NASH-associated T-
cell responses, we took advantage of transgenic TACI-Ig mice that overexpress a soluble form of 
the BAFF/APRIL receptor TACI and are characterized by the selective depletion of B2-lymphocytes 
[25]. In our hands, TACI-Ig mice showed a marked lowering of hepatic B-cells specifically involving 
the B220+/CD43-/CD23+ B2-subset (Supplementary Fig. 5A). Conversely, no significant changes 
were appreciable in the fraction of B220+/CD43+/CD23- B1-cells (Supplementary Fig. 5B). Upon the 
induction of NASH, we observed that liver plasma cell maturation, as well as the production of 
anti-OSE IgG, were impaired in TACI-Ig mice as compared to wild-type littermates (Fig. 3A-B). In 
line with a role of B2-cells in promoting T-cell responses, the liver recruitment of CD4+ and CD8+ T-
lymphocytes, as well as their CD69 expression, were significantly reduced in TACI-Ig mice receiving 
the MCD diet (Fig. 3C-D), in spite the expansion and activation of hepatic dendritic cells were not 
affected (Supplementary Fig. 5C). Moreover, the hepatic expression of Th-1 activation markers 
IFN-γ, CD154 and T-bet was also decreased in TACI-Ig mice (Fig. 3E). These effects were specific for 
liver immune responses associated with NASH, as no difference in the development of anti-OSE 
immunity were evident between wild-type and TACI-Ig mice following immunization with bovine 
serum albumin complexed with malonyl-dialdehyde (Fig. 4). The lack of B2-cells in TACI-Ig mice 
also appreciably ameliorated lobular inflammation score (2.3±0.5 vs 1.6±0.5; p<0.05) and the 
prevalence of necrotic foci (7.3±3.31 vs 4.0±1.3; p<0.05) without affecting the extension of 
steatosis (2.8±0.4 vs 2.5±0.5; p=0.39). 
 
Effects of BAFF neutralization ameliorates the evolution of NASH 
Previous studies have shown that circulating levels of BAFF are higher in patients with NASH than 
in those with simple steatosis, and correlate with the severity of steatohepatitis and fibrosis [28].  
Thus, to investigate the effects of interfering with BAFF on the evolution of steatohepatitis, we 
performed additional experiments taking advantage of the BAFF neutralizing monoclonal antibody 
Sandy-2 [26]. In preliminary tests we observed that treatment for one week with Sandy-2 (2 µg/g 
body weight) reduced by about 40% circulating and liver B-cells, specifically affecting the B2-
subset (Supplementary Fig. 6A-B). Accordingly, the administration of Sandy-2 prevented liver 
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plasma cell maturation in mice fed with the MCD diet for 1 week (Supplementary Fig. 6C). In the 
animals receiving the MCD diet for 4 weeks, BAFF neutralization ameliorated histological scores 
for steatosis (2.8±0.4 vs 1.7±0.8; p<0.05) and lobular inflammation (2.7±0.5 vs 1.8±0.4; p<0.05) as 
well as ALT release and liver triglycerides (Fig. 5 A-C). Differently from what observed in TACI-Ig 
mice, Sandy-2 treatment did not appreciably affect the prevalence of liver infiltrating CD4+ and 
CD8+ T-cells (not shown). Nonetheless, Th-1 activation of liver CD4+ T-lymphocytes, as evaluated 
by IFN-γ production, was significantly lowered by Sandy-2 treatment (Fig. 5D). BAFF blockage also 
decreased the hepatic expression of pro-inflammatory mediators such as TNF-α, IL-12 and CXCL10 
(Fig. 5E). 
 
Role of B-lymphocyte in NASH progression to fibrosis 
Besides the improvement of hepatic inflammation, MCD-fed mice receiving Sandy-2 showed a 
descending trend in the expression of pro-fibrotic markers α1-procollagen and α-smooth muscle 
actin (α-SMA) (Fig.5F), although the differences did not reach statistical significance. Since keeping 
mice under the MCD diet to the time required for the development of hepatic fibrosis leads to 
severe weight loss, we switched to the CDAA diet to investigate whether the lack of B2-
lymphocytes would affect the fibrogenic evolution of NASH in TACI-Ig mice. Such an experimental 
model allows, in fact to reproduce NASH-associated fibrosis avoiding weight loss [29].    We 
observed that CDAA-fed TACI-Ig mice had hepatic expression of α1-procollagen, α-SMA and 
Transforming Growth Factor-β1 (TGF-β1) significantly lower than wild-type littermates (Fig. 6A). 
Consistently, Sirius Red staining for collagen and the prevalence of α-SMA-positive activated 
hepatic stellate cells were also significantly reduced in TACI-Ig mice (Fig. 6 B-D). The improvement 
of fibrosis observed in CDAA-fed TACI-Ig mice was associated with a lowering of transaminases 
release and lobular inflammation (Supplementary Fig. 7), supporting the importance of B-cells in 
the mechanisms leading to steatohepatitis progression. 
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Discussion 
Growing evidence suggests that adaptive immunity is implicated in the processes responsible for 
the evolution of NAFLD to hepatic fibrosis and HCC [30]. In this setting, Zhang and co-workers have 
recently reported that feeding a high fat diet to mice leads to the liver recruitment of cells from B 
lineage (B220+) producing pro-inflammatory cytokines [31]. However, this work did not investigate 
the actual role of B-cells in the pathogenesis of steatohepatitis.  Our present data address this 
aspect by showing that B-cell activation is an early event in the evolution of experimental NASH 
and, even in the absence of obesity, contributes in supporting immune responses associated with 
the progression of steatohepatitis.  
B-cells represent about 50% of intrahepatic lymphocytes. However, so far conflicting results have 
been obtained in studies investigating their role in liver diseases [32-34]. In mice, the pool of liver 
B-lymphocytes mainly consists of bone marrow-derived mature B220+/IgM+/CD23+/CD43- B2-cells 
resembling spleen follicular B-cells [32]. We have observed that B-cell changes in NASH specifically 
involve the B2 compartment and are characterized by their maturation to plasma cells. The 
circulating levels of IgG targeting OSE also increase at the onset of experimental NASH, suggesting 
that oxidative damage associated with the development of steatohepatitis leads to the generation 
of antigens recognized by B-cells that then undergo maturation to IgG-producing plasma cells.   
The actual relevance of B-cell responses in the pathogenesis of NASH is supported by experiments 
using B2-cell-deficient TACI-Ig mice or by using the BAFF neutralizing antibody Sandy-2.  In these 
settings, B2-cell depletion or the interference with BAFF-mediated survival and maturation of B2- 
cells ameliorates both parenchymal damage and lobular inflammation and reduces the 
development of fibrosis.  Interestingly B-cell maturation to plasma cells has been recently shown 
to foster HCC development in mice with steatohepatitis [35].  The beneficial effects connected 
with the interference with B-cell survival/maturation likely depend upon the reduction in the 
production of pro-inflammatory mediator by B-lymphocytes [36] as well as the impairment of their 
antigen presenting capabilities [37]. On this latter respect, we have observed that B-cell activation 
in NASH associates with the up-regulation in MHCII molecules in plasma blasts and precedes the 
liver recruitment of CD4+ and CD8+ T-lymphocytes, while interfering with B2-cells reduces Th-1 
activation of CD4+ T cells without affecting the maturation of dendritic cell. Altogether these 
results suggest that B2-lymphocytes can have a role in promoting OSE presentation to T-cells that, 
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in turn, support NASH progression [9,10]. Indeed, B-cells express a variety of receptors that can 
recognize OSE [38], while Béland and co-workers [34] have reported that B-cell depletion with 
anti-CD20 antibodies ameliorates experimental autoimmune hepatitis by preventing autoantigen 
presentation to CD4+ and CD8+ T-cells.   
It is noteworthy that the above mechanisms have several analogies with that observed in 
atherosclerosis, where B2-lymphocytes activation by OSE represents a key mechanism in plaque 
evolution. In fact, elevated circulating titers of anti-OSE IgG associate with an enhanced risk of 
atherosclerosis complications in humans [39], whereas the interference with B2-cells or BAFF-
mediated signals reduces experimental atherosclerosis [39,40]. Although NAFLD/NASH is 
increasingly recognized as an independent risk factor for cardiovascular diseases [3], it is still 
unclear whether such association might be related to the common involvement of OSE-mediated 
immune responses. The studies on atherosclerosis have also outlined a dual role of B-cells in the 
disease evolution. In one hand, in fact, B2-cells promote plaque evolution by supporting humoral 
and cellular anti-OSE immunity, while the activation of the B1 subset exerts a protective action 
mainly through the production of natural antibodies capable of scavenging pro-atherogenic 
oxidized low density lipoproteins (LDL) [39,40]. Natural antibodies are pre-existing germline 
encoded antibodies belonging to the IgM class with a broad specificity to pathogens, but also able 
to cross-react with endogenous antigens, such as OSE in oxidized LDL [39]. In line with these 
notions, studies by Binder’s group have shown that B1-lymphocytes can affect the severity of 
steatohepatitis in LDL receptor-deficient mice fed with high fat/cholesterol diet [41,42]. Such 
effects have been ascribed to the capacity of B1-lymphocytes to produce IgM cross-reacting with 
OSE that prevent oxidized LDL accumulation within liver macrophages and their pro-inflammatory 
activation due to cholesterol engulfment [41]. In our hands, liver B1-cells, as well as circulating 
IgM, are not modified during NASH evolution, while TACI over-expression or Sandy-2 treatment do 
not affect the B1-compartment. Nonetheless, the combination of our present data and those by 
Binder’s group suggests the possibility that B1- and B2-cells might have antagonist activities also in 
the pathogenesis of NAFLD/NASH, with B2-lymphocytes being involved in promoting pro-
inflammatory mechanisms and the B1 subset possibly exerting a protective action. Opposite B1/B2 
actions have also recently documented in relation to B-lymphocytes involvement in promoting 
obesity-associated adipose tissue inflammation and insulin resistance [43,44]. Such a duality will 
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need to be considered in future studies addressing the role of B-cells in NAFLD, also in relation to 
the fact that both subsets can give rise to regulatory B-lymphocytes [45].   
Although the interference with cytotoxic and inflammatory mechanisms might account for the 
improvement in liver fibrosis observed in B2-cell-deficient TACI-Ig mice with NASH, we cannot 
exclude that additional mechanisms might also be involved. In fact, previous studies indicate that 
B-cells can directly contribute to liver fibrogenesis [32,46] through the production of pro-
inflammatory mediators that stimulate hepatic stellate cell (HCS) and liver macrophage activation 
[46].  On the other hand, Thapa and co-workers have reported that during chronic liver injury 
activated HSCs can support liver B-cell survival and maturation to plasma cells by secreting retinoic 
acid [46], thus suggesting a complex interplay between B-cells and other non-parenchymal cells in 
the evolution of chronic liver diseases.  
The capacity of B-cells to stimulate inflammation and fibrogenesis through multiple interactions 
with T-lymphocytes and HSCs accounts for our clinical observations, showing that the prevalence 
of B-/T-lymphocyte aggregates in liver biopsies of NAFLD/NASH patients correlates with more 
severe lobular inflammation and enhanced fibrosis. In these subjects, intra-hepatic B/T-cell 
aggregates are also associated with elevated titers of anti-OSE IgG and high IFN-γ circulating levels, 
further supporting the clinical relevance of the interplay between B- and T-cells in the processes 
leading to NAFLD/NASH progression. 
 
Conclusions 
Altogether these data indicate that B2-lymphocyte activation in response to OSE is an early event 
in NASH evolution and contributes to sustain hepatic inflammation through the interaction with T-
cells.  These observations, along with previous data indicating anti-OSE IgG as an independent risk 
factor for NASH progression to advanced fibrosis [17], suggest that the measure of circulating anti-
OSE IgG can identify a sub-set of NAFLD/NASH patients in whom adaptive immunity triggered by 
oxidative stress might have a relevant role in promoting steatohepatitis and the disease evolution 
toward fibrosis.   If confirmed in prospective studies, IgG reactivity toward OSE might become a 
useful non-invasive marker for the identification of this sub-set of NAFLD patients who might 
benefit from already available treatments that interfere with B-cell functions.     
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Fig 1:  B- and T-lymphocyte responses associates with the evolution of human NAFLD/NASH. (A-C) 
IgG reactivity toward OSE was measured in 41 NAFLD/NASH patients by in house ELISA assay using 
as antigen malonyl-dialdehyde (MDA) adducts with human serum albumin. For comparison 32 and 
18 age/gender matched healthy subjects were used as controls.  Circulating interferon-γ (IFN-γ) 
was measured in 34 of the patients and 18 age/gender matched healthy subjects. (D) Immuno-
histochemical detection of cell aggregates containing CD20+ B-lymphocytes and CD3+ T-
lymphocytes in serial sections from liver biopsies of two different representative NAFLD/NASH 
patients (Magnification 400x). (D-F) The prevalence of B/T-cells aggregates was associated with 
anti-OSE IgG titers as well as with the severity of lobular inflammation and hepatic fibrosis as 
estimated according to Kleiner et al. (24). Lymphocyte infiltration was evaluated semi-
quantitatively taking into account the number and size of lymphocyte aggregates.  
Fig 2:  B-cell responses during the evolution of experimental NASH. Wild type mice were fed with 
the MCD diet for either 1 or 4 weeks. The intrahepatic distribution of B-lymphocytes, plasma 
blasts and plasma cells were evaluated by flow cytometry in parallel with the production of IgG 
targeting OSE and the liver expression of BAFF. (A) Changes in the liver distribution of total 
IgM+/B220+ B-lymphocytes at different stages of NASH evolution. (B) Changes in the liver 
distribution of B220+/CD138+ plasma blasts and B220-/CD138+ plasma cells at different stages of 
NASH evolution. The values are means ± SD of three different experiments with 3-4 animals per 
group. (C-D) changes in anti-OSE antibody titres, as measured by IgG and IgM targeting malonyl-
dialdehyde (MDA) adducts in the sera of mice with NASH. The values in panels C and D are means 
± SD of 8-10 animals per group and the boxes include the values within 25th and 75th percentile, 
while the horizontal bars represent the median. The extremities of the vertical bars (10th-90th 
percentile) include 80% of the values.   
Fig 3: B2-lymphocyte deficiency interferes with the onset of immune responses in NASH. B2-cell 
deficient TACI-Ig and wild type mice were fed with control or MCD diet for 4 weeks. The 
intrahepatic distribution of T-lymphocytes and plasma cells was evaluated by flow cytometry in 
parallel with the production of IgG targeting OSE and the liver expression of Th-1 activation 
markers. (A) Effect of B2-cell depletion on the liver expansion of B220-/CD138+ plasma cells and (B) 
the increase of circulating anti-OSE antibody titres, as measured by IgG targeting malonyl-
dialdehyde (MDA) adducts. (C) The liver distribution of CD4+ and CD8+ T-lymphocytes and (D) their 
expression of the activation marker CD69 in TACI-Ig and wild-type mice with NASH. The values in 
panels A-C are means ± SD of three different experiments with 3-4 animals for each group. (E) 
Down-modulation in the expression of Th-1 activation markers interferon-γ (IFN-γ), T-bet and 
CD40 ligand (CD154) in the liver of TACI-Ig mice. The values of RT-PCR analysis are expressed as 
fold increase over their relative controls and are means ± SD of 8-10 animals per group. The boxes 
in panels B and E include the values within 25th and 75th percentile, while the horizontal bars 
represent the median. The extremities of the vertical bars (10th-90th percentile) include 80% of the 
values. 
Fig 4:  B2-cell deficiency in TACI-Ig mice does not affect the development of anti-OSE immunity. 
Wild-type and TACI-Ig mice were immunized with bovine serum albumin adducted with 
malonyldialdehyde (MDA) and incomplete Freund’s adjuvant as previously reported [10]. (A) 
Lymphocytes were isolated from spleens of naïve and immunized animals and the production of 
IFN-γ and IL-2 by CD4+ T-lymphocytes was evaluated by flow cytometry. One experiment 
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representative of two. (B) Circulating IgG targeting MDA adducts were measured by ELISA assay in 
the sera of the same animals. The bars represent medians ± S.D.  
Fig 5: Mice treatment with the BAFF-neutralizing antibody Sandy-2 ameliorates steatohepatitis. 
Wild type mice were injected with Sandy-2 mAb (2 µg/g body weight) or isotype-matched IgG at 
the start and after 2 weeks of MCD diet. (A) Haematoxylin/eosin staining of liver sections 
(Magnification 200x). (B) Alanine aminotransferase (ALT) release and (C) liver triglyceride content. 
(D) Flow cytometry evaluation of interferon-γ (IFN-γ) production by CD3+/CD4+ helper T-
lymphocytes. The values are means ±SD of three different experiments with 4 animals per group. 
The hepatic mRNA levels of (E) pro-inflammatory mediators TNF-α, IL-12p40 and CXCL10 and (D) 
fibrosis markers α1-procollagen and α-smooth muscle actin (α-SMA). RT-PCR values are expressed 
as fold increase over control values after normalization to the β-actin gene. The values in the 
panels B, C, E and F refer to 6-7 animals per group and the boxes include the values within 25th and 
75th percentile, while the horizontal bars represent the median. The extremities of the vertical 
bars (10th-90th percentile) include 80% of the values. 
Fig 6: B2-lymphocyte deficiency reduces NASH evolution to fibrosis. TACI-Ig and wild type (WT) 
mice were fed with either control or CDAA diets for 24 weeks. (A) Hepatic expression of 
fibrogenesis markers α1-procollagen, α-smooth muscle actin (α-SMA) and Transforming Growth 
Factor-β1 (TGF-β1). RT-PCR values are expressed as fold increase over control values after 
normalization to the β-actin gene. (B) Collagen deposition as detected by Sirius Red staining in 
representative liver sections from 24-week CDAA diet in WT and TACI-Ig mice (Magnification 
200x). (C) Immuno-histochemical staining for α-SMA-positive hepatic stellate cells (HSCs) liver 
sections from 24-week CDAA diet in WT and TACI-Ig mice (Magnification 200x). (D) Histo-
morphometric analysis of Sirius Red and α-SMA positive areas. The values refer to 5-7 animals per 
group and the boxes include the values within 25
th
 and 75
th
 percentile, while the horizontal bars 
represent the median. The extremities of the vertical bars (10
th
-90
th
 percentile) include 80% of the 
values. 
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 Liver B/T-cell infiltration identify NAFLD patients with advanced disease. 
 Oxidative stress-derived antigens promote IgG production in NAFLD patients 
 Hepatic B2-cells activation to plasma cells characterizes the onset of steatohepatitis. 
 Selective B2-cell depletion prevents Th-1 activation of liver CD4+ T-lymphocytes.  
 Interference with B2-cells improve NAFLD evolution to fibrosis.  
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